The potential role of FDG PET-CT in the characterization of the activity of Crohn’s disease, staging follow-up and prognosis estimation: a pilot study

References

• Bettenworth D, Reuter S, Hermann S, et al. Translational 18F-FDG PET/CT imaging to monitor lesion activity in intestinal inflammation. J Nucl Med. 2013;54:748–755.
   PubMed Web of Science ®Google Scholar
• Groshar D, Bernstine H, Stern D, et al. PET/CT enterography in Crohn disease: correlation of disease activity on CT enterography with 18F-FDG uptake. J Nucl Med. 2010;51:1009–1014.
   PubMed Web of Science ®Google Scholar
• Meisner RS, Spier BJ, Einarsson, et al. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:993–1000.
   PubMed Web of Science ®Google Scholar
• Louis E, Ancion G, Colard A, et al. Noninvasive assessment of Crohn’s disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med. 2007;48:1053–1059.
   PubMed Web of Science ®Google Scholar
• Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301–1306.
   PubMed Web of Science ®Google Scholar
• Love C, Tomas MB, Tronco GG, et al. FDG PET of infection and inflammation. Radiographics. 2005;25:1357–1368.
   PubMed Web of Science ®Google Scholar
• Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31:496–505.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Vehling D, Schunk K, et al. Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labelled antibodies. Am J Gastroenterol. 2002;97:1978–1985.
   PubMed Web of Science ®Google Scholar
• Das CJ, Makharia G, Kumar R, et al. PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine. Eur J Nucl Med Mol Imaging. 2007;34:2106–2114.
   PubMed Web of Science ®Google Scholar
• Ahmadi A, Li Q, Muller K, et al. Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography enterography in active Crohn’s disease. Inflamm Bowel Dis. 2009;16:974–981.
   Web of Science ®Google Scholar
• Jacene HA, Ginsburg P, Kwon J, et al. Prediction of the need for surgical intervention in obstructive Crohn’s disease by 18F-FDG PET/CT. J Nucl Med. 2009;50:1751–1759.
   PubMed Web of Science ®Google Scholar
• Spier BJ, Perlman SB, Reichelderfer M. FDG-PET in inflammatory bowel disease. Q J Nucl Med Mol Imaging. 2009;53:64–71.
   PubMed Web of Science ®Google Scholar
• Treglia G, Quartuccio N, Sadeghi R, et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with chronic inflammatory bowel disease: a systematic review and a meta-analysis. J Crohns Colitis. 2013;7:345–354.
   PubMed Web of Science ®Google Scholar
• Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol. 2005;3:11–24.
   PubMed Web of Science ®Google Scholar
• Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.
   PubMed Web of Science ®Google Scholar
• Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7:556–585.
   PubMed Web of Science ®Google Scholar
• Paquet N, Albert A, Foidart J, et al. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784–788.
   PubMed Web of Science ®Google Scholar
• Loffler M, Weckesser M, Franzius C, et al. High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci. 2006;1072:379–385.
   PubMed Web of Science ®Google Scholar
• Spier BJ, Perlman SB, Jaskowiak CJ, et al. PET/CT in the evaluation of inflammatory bowel disease: studies in patients before and after treatment. Mol Imaging Biol. 2010;12:85–88.
   PubMed Web of Science ®Google Scholar
• af Bjorkesten CG, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2012;47:528–537.
   PubMed Web of Science ®Google Scholar
• Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT). Arch Dermatol. 2011;147:1031–1039.
   PubMedGoogle Scholar
• Youn SW, Kang SY, Kim SA, et al. Subclinical systemic and vascular inflammation detected by (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with mild psoriasis. J Dermatol. 2015;42:559–566.
   PubMed Web of Science ®Google Scholar
• Lenze F, Wessling J, Bremer J, et al. Detection and differentiation of inflammatory versus fibromatous Crohn’s disease strictures: prospective comparison of 18F-FDG-PET/CT, MR-enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation IBD. Inflamm Bowel Dis. 2012;18:2252–2260.
   PubMed Web of Science ®Google Scholar
• Chacko AM, Watanabe S, Herr KJ, et al. 18F-FDG as an inflammation biomarker for imaging dengue virus infection and treatment response. JCI Insight. 2017;2:e93474.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45:872–877.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Bjorkesten CG, Farkkila M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol. 2010;45:325–331.
   PubMed Web of Science ®Google Scholar
• Saboury B, Salavati A, Brothers A, et al. FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging. 2014;41:605–614.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Patel CN, Scarsbrook AF, et al. FDG PET/CT in infection and inflammation-current and emerging clinical applications. Clin Radiol. 2015;70:787–800.
   PubMed Web of Science ®Google Scholar
• Pellino G, Nicolai E, Catalano OA, et al. PET/MR versus PET/CT imaging: impact on the clinical management of small-bowel Crohn’s disease. J Crohns Colitis. 2016;10:277–285.
   PubMed Web of Science ®Google Scholar